Processing of chimeric antisense oligonucleotides by human vascular smooth muscle cells and human atherosclerotic plaque: Implications for antisense therapy of restenosis after angioplasty

Circulation

Volumn 93, Issue 4, 1996, Pages 772-780

  Pickering, J Geoffrey ^a,c   Isner, Jeffrey M ^b   Ford, Carol M ^a   Weir, Lawrence ^b   Lazarovits, Andrew ^a   Rocnik, Edward F ^a   Chow, Lawrence H ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

angioplasty; genes; muscle, smooth

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE;

ANGIOPLASTY; ARTERY INJURY; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHIMERA; DNA SYNTHESIS; GENE EXPRESSION; GENETIC LINKAGE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN PROCESSING; RESTENOSIS; RNA SEQUENCE; VASCULAR SMOOTH MUSCLE;

EID: 0030054122     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.4.772     Document Type: Article

References (42)

1. Stein CA, Cohen JS. Oligonucleotides as inhibitors of gene expression. Cancer Res. 1988;48:2659-2668.
2. Toulmé J, Hélene C. Antimessenger oligodeoxynucleotides: an alternative to antisense RNA for artificial regulation of gene expression: a review. Gene. 1988;72:51-58.
3. Bayever E, Iverson P, Smith L, Spinolo J, Zon G. Systemic human antisense therapy begins. Antisense Res Der. 1992;2:109-110.
4. Reynolds T. First antisense drug trials planned in leukemia. J Natl Cancer Inst. 1992;84:288-290.
5. Simons M, Rosenberg RD. Antisense nonmuscle myosin heavy chain and c-myb oligonucleotides suppress smooth muscle cell proliferation in vitro. Circ Res. 1992;70:835-843.
6. Speir E, Epstein SE. Inhibition of smooth muscle cell proliferation by antisense oligodeoxynucleotide targeting by the messenger RNA encoding proliferating cell nuclear antigen. Circulation. 1992;86: 538-547.
7. Shi Y, Hutchison HG, Hall DJ, Zalewski A. Downregulation of c-myc expression by antisense oligonucleotides inhibits proliferation of human smooth muscle cells. Circulation. 1993;88: 1190-1195.
8. Biro S, Fu Y-M, Yu Z-X, Epstein S. Inhibitory effects of oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Proc Natl Acad Sci USA. 1993;90:654-658.
9. Simons M, Edelman ER, DeKeyser J, Langer R, Rosenberg RD. Antisense c-myb oligonucleotides inhibit arterial smooth muscle cell accumulation in vivo. Nature. 1992;359:67-70.
10. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA. 1993;90:8474-8478.
11. Morishita R, Gibbons GH, Ellison KE, Nakajima M, von der Leyen H, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Intimai hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotide. J Clin Invest. 1994;93:1458-1464.
12. Bennet MR, Anglin S, McEwan JR, Jagoe R, Newby AC, Evan GI. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J Clin Invent. 1994;93:820-828.
13. Shi Y, Fard A, Galeo A, Hutchinson HG, Vermani P, Dodge GR, Hall DJ, Shaheen F, Zalewski A. Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation. 1994;90: 944-951.
14. Simons M, Edelman E, Rosenberg R. Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimai hyperplasia in a rat carotid artery injury model. J Clin Invest. 1994;93:2351-2356.
15. Epstein SE, Speir E, Finkel TF. Do antisense approaches to the problem of restenosis make sense? Circulation. 1993;88:1351-1353.
16. Stein CA, Cheng Y-C. Antisense oligonucleotides as therapeutic agents: is the bullet really magical? Science. 1993;261:1004-1012.
17. Villa AE, Guzman LA, Poptic EP, Labhasetwar V, D'Souza S, Farrell CL, Plow EF, Levy RJ, DiCorleto PE, Topol EJ. Effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury. Circ Res. 1995;76: 505-513.
18. Noonberg SB, Garavoy MR, Hunt CA. Characteristics of oligonucleotide uptake in human keratinocyte cultures. J Invest Dermatol. 1993;101:727-731.
19. Isner JM, Kearney M, Bauters C, Leclerc G, Pickering JG, Reissen R, Weir L. Use of human tissue specimens obtained by directional atherectomy to study restenosis. Trends Cardiovasc Med. 1994;4: 213-221.
20. Feigner PL, Gadak TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielson M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA. 1987;84:7413-7417.
21. Gao W-C, Han F-S, Storm C, Egan W, Cheng Y-C. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerase and RNase H: implications for antisense technology. Mol Pharmacol. 1992;42:223-229.
22. Shaw JP, Kent K, Bird J, Fishback J, Froehler B. Modified deoxyoligonucleotides stable to exonuclease degradation in serum. Nucleic Acids Res. 1991;19:747-750.
23. Jaskulski D, DeRiel J, Mercer E, Calabretta B, Baserga R. Inhibition of cellular proliferation by antisense oligodeoxynucleotides to PCNA cyclin. Science. 1988;240:1544-1546.
24. Pickering JG, Weir L, Jekanowski J, Kearney M, Isner JM. Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revascularization. J Clin Invest. 1993;91:1469-1480.
25. Pickering JG, Weir L, Rosenfield K, Stetz J, Jekanowski J, Isner JM. Smooth muscle cell outgrowth from human atherosclerotic plaque: implications for the assessment of lesion biology. J Am Coll Cardiol. 1992;20:1430-1439.
26. Shoji Y, Akhtar S, Periasamy A, Herman B, Juliano RJ. Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. Nucleic Acids Res. 1991;19:5543-5550.
27. Holt CE, Garlick N, Cornel E. Lipofection of cDNAs in the embryonic vertebrate central nervous system. Neuron. 1990;4: 203-214.
28. Renfrew CA, Hubbard AL. Degradation of epidermal growth factor receptor in rat liver: membrane topology through the lysosomal pathway. J Biol Chem. 1991;266:21265-21273.
29. Bravo R, Macdonald-Bravo H. Existence of two populations of cyclin/proliferating cell nuclear antigen during the cell cycle: association with DNA replication sites. J Cell Biol. 1987;105:1549-1554.
30. Cazenave C, Stein CA, Loreau N, Thuong NT, Neckers LM, Subasinghe C, Hélene C, Cohen JS, Toulmé JJ. Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides. Nucleic Acids Res. 1989;19: 4255-4273.
31. Stein CA, Tonkinson JL, Zhang L, Yakubov L, Gervasoni J, Taub R, Rotenberg SA. Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. Biochemistry. 1993; 32:4855-4861.
32. Neckers L, Whitesell L, Rosolen A, Geselowitz DA. Antisense inhibition of oncogene expression. Crit Rev Oncog. 1992;3:175-231.
33. Ho PTC, Bacon TA, Wickstrom E, Sartorelli AC. Efficacy of antisense phosphodiester and phosphorothioate oligodeoxyribonucleotides to the transferrin receptor correlates with serum stability and cellular uptake. J Cell Biol. 1989;107:329a. Abstract.
34. Loke SL, Stein CA, Zhang XH, Mori K, Nakanishi M, Subasinghe C, Cohen JS, Neckers LM. Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci USA. 1989;86: 3474-3478.
35. Yakubov LA, Deeva EA, Zarytova VF, Ivanova EM, Ryte AS, Yurchenko LV, Vlassov VV. Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proc Natl Acad Sci USA. 1989;86:6454-6458.
36. Boutorin AS, Guslova LV, Ivanova EM, Kobetz ND, Zarytova VF, Ryte AS, Yurchenko LV, Vlassov VV. Synthesis of alkylating oligonucleotide derivatives containing cholesterol or phenazium residues at their 3′ terminus and their interaction with DNA within mammalian cells. FEBS Lett. 1989;254:129-132.
37. Goodchild J, Lestsinger RL, Sarin PS, Zamecnik M, Zamecnik PC, eds. Human Retroviruses, Cancer and AIDS: Approaches to Prevention and Therapy. New York, NY: Alan R Liss Inc; 1988:423-438.
38. Leonetti JP, Mechti N, Degols G, Gagnor C, Lebleu B. Intracellular distribution of microinjected antisense oligonucleotides. Proc Natl Acad Sci USA. 1991;88:2702-2706.
39. Chin DJ, Green GA, Zon G, Szoka FC, Straubinger RM. Rapid nuclear accumulation of injected oligodeoxyribonucleotides. New Biologist. 1990;2:1091-1100.
40. Kulka M, Smith CC, Aurelian L, Fishelevich R, Meade K, Miller P, Ts'o POP. Site specificity of the inhibitory effects of oligo-(nucleoside methylphosphonate)s complementary to the acceptor splice junction of herpes simplex virus 1 immediate early mRNA4. Proc Natl Acad Sci USA. 1989;86:6868-6872.
41. McManaway ME, Neckers LM, Loke LS, Al-Naeser AA, Redner RI, Shirmizo BT, Goldschmidts WI, Huber BE, Bhatia K, Magrath IT. Tumor-specific inhibition of lymphoma growth by antisense oligodeoxynucleotide. Lancet. 1990;1:808-810.
42. Wagner EL, Zatloukal K, Cotten M, Kirlappos H, Mechtler K, Curiel DT, Birnsteil ML. Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc Natl Acad Sci U S A. 1992;89:6099-6103.